Amphastar Pharmaceuticals Inc Stock News

Floyd Petersen exercised and sold 16,679 shares of Amphastar in November, pocketing more than $441,000. He still retains about $2 million worth of shares.

RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for teriparatide injection, USP 560 mcg/2.24mL (250 mcg/mL) single-patient-use prefilled pen. The FDA determined that Amphastar's teriparatide is bioequivalent ...

RANCHO CUCAMONGA, CA / ACCESS Newswire / November 24, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be participating in an Analyst-Moderated fireside chat at the 37th Annual Piper Sandler Healthcare Conference on Wednesday, December 3rd, 2025, at 2:00 pm ET. For access, visit Am...

RANCHO CUCAMONGA, CA / ACCESS Newswire / November 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be participating in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Wednesday, November 19th, 2025, at 3:30 pm GMT. For access, visit Amphastar's Pharmace...

Amphastar Pharmaceuticals, Inc. ( AMPH ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate Communication William Peters - CFO, Executive VP of Finance, Treasurer & Director Tony Marrs - Executive VP of Regulatory Affairs & Clinical Operations Conference Call Participants Serge Belanger - Needham & Company,...

Reports Net Revenues of $191.8 million for the Three Months Ended September 30, 2025 GAAP net income of $17.4 million, or $0.37 per share, for the third quarter Adjusted non-GAAP net income of $44.7 million, or $0.93 per share, for the third quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA / ACCESS Newswire / November 6, 2025 / Amphastar Pharmaceuti...

RANCHO CUCAMONGA, CA / ACCESS Newswire / October 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2025 ended September 30, 2025, after the market closes on Thursday, November 6, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

Amphastar Pharmaceuticals is rated a buy due to strong Q2 earnings, value metrics, and promising pipeline developments. AMPH beat revenue and EPS estimates in Q2, with BAQSIMI sales up 21% YoY, offsetting declines in legacy generics. The company is vastly expanding US manufacturing and advancing new drugs, including AMP-002 (recently FDA approved) and AMP-004 (insulin aspart generic).